Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bevacizumab + Fluorouracil + IGM-8444 + Irinotecan + Leucovorin|
|Synonyms||Bevacizumab + FOLFIRI + IGM-8444|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bevacizumab||Avastin||VEGF Antibody 9 VEGFR Inhibitor (Pan) 33||Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).|
|Fluorouracil||Adrucil||5-FU||Chemotherapy - Antimetabolite 14||Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).|
|IGM-8444||IGM8444|IGM 8444||IGM-8444 is a multivalent agonistic antibody that targets and activates Death Receptor 5 (TNFRSF10B), potentially resulting in increased cytotoxicity and apoptosis, and inhibition of tumor growth (Journal of Clinical Oncology 2020 38:15_suppl, 3595; Cancer Res 2020;80(16 Suppl):Abstract nr 518).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 10||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Leucovorin||Wellcovorin||Calcium folinate|Calcium citrovorum factor|folinic acid||Chemotherapy - Antimetabolite 14||Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04553692||Phase I||Bevacizumab + Fluorouracil + IGM-8444 + Irinotecan + Leucovorin Fluorouracil + IGM-8444 + Irinotecan + Leucovorin IGM-8444||Study of IGM-8444 as a Single Agent and in Combination With Chemotherapy-based Regimens in Subjects With Solid Cancers||Recruiting||USA||0|